5068202026-04-012026-06-305068202026-04-012026-06-30in-capmkt:OtherExpenses1Member5068202026-04-012026-06-30in-capmkt:OtherExpenses2Member5068202026-04-012026-06-30in-capmkt:OtherExpenses3Member5068202026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares506820ASTRAZENNAINE203A01020ASTRAZENECA PHARMA INDIA LIMITEDMain BoardEquity2026-04-012027-03-312026-08-102026-08-04INRMillionsQuarterlyFirst quarterSingle segmentHealthcare2026-08-1011:15:002026-08-1013:40:00Not applicablefalsefalse1-The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. <br /> 2-The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. <br /> 3-During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. <br /> 4-The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year i.e 31 March 2026 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e 31 December 2025 which were subjected to limited review by the statutory auditors. <br /> 5-Exceptional items for the quarter ended 30 June 2026 , 31 March 2026 and 30 June 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 3 above) <br /> 6-Subsequent to quarter end, the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 Million (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Based on evaluation, Management is of the view that there are reasonable grounds to challenge the same. Accordingly, management has assessed and concluded this matter as a contingent liability and no provision has been recorded in these financial results. <br /> 7-Subsequent to the end of the quarter, the Company has received from a third party an amount of Rs. 100 million, recognised as other income in July 2026, towards compensation for commercial losses. Based on its assessment in accordance with Ind AS, the Company has determined that the aforesaid receipt constitutes a non-adjusting event after the reporting period. Accordingly, no adjustment has been made to these financial results. <br /> 8-This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2026.2026-04-012026-06-30UnauditedStandalone6827900000923000006920200000030462000001425900000791600000195000005230000010748000006410300000509900000-24000005075000001087000001950000012820000003793000000000379300000-300000037630000050000000215.1700015.170Notes: <br /> <br /> 1 The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the “Act”) [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India. <br /> <br /> 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided. <br /> <br /> 3 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company’s manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site. <br /> <br /> 4 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year i.e 31 March 2026 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e 31 December 2025 which were subjected to limited review by the statutory auditors. <br /> 5 Exceptional items for the quarter ended 30 June 2026 , 31 March 2026 and 30 June 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 3 above). <br /> <br /> 6 Subsequent to quarter end, the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 Million (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Based on evaluation, Management is of the view that there are reasonable grounds to challenge the same. Accordingly, management has assessed and concluded this matter as a contingent liability and no provision has been recorded in these financial results. <br /> <br /> 7 Subsequent to the end of the quarter, the Company has received from a third party an amount of Rs. 100 million, recognised as other income in July 2026, towards compensation for commercial losses. Based on its assessment in accordance with Ind AS, the Company has determined that the aforesaid receipt constitutes a non-adjusting event after the reporting period. Accordingly, no adjustment has been made to these financial results. <br /> <br /> 8 This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2026. <br /> <br /> By Order of the Board of Directors <br /> For AstraZeneca Pharma India Limited <br /> <br /> <br /> <br /> <br /> Place: Bengaluru Praveen Rao Akkinepally <br /> Date: 10 August 2026 Managing Director <br /> Allowance for expected credit loss (net)26000000Selling, marketing and distribution expense307500000Others741300000Re-measurement gains / (losses) on post employment benefit obligations-4000000-4000000-10000000-3000000